Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aurinia Pharmaceuticals Inc AUPH

Healthcare  —  Biotechnology
16.44 (0.16) (0.96%) as of 25 Sep
Market cap
$2.2B
P/E
6.9×
Cash Flow Champion (3y) Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aurinia Pharmaceuticals Inc (AUPH) Business Profile

Updated before January 2025

Company Overview

Aurinia Pharmaceuticals Inc. (AUPH) is a biopharmaceutical company dedicated to developing and commercializing therapies for autoimmune diseases. Founded in 1993 and headquartered in Victoria, British Columbia, Canada, Aurinia has established itself as a leader in the treatment of rare and serious autoimmune conditions. The company is publicly traded on the NASDAQ under the ticker symbol AUPH.

Aurinia’s leadership team is composed of seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. The company’s CEO, Peter Greenleaf, has been instrumental in driving Aurinia’s strategic vision and growth. Under his leadership, the company has successfully transitioned from a development-stage organization to a commercial-stage enterprise. Other key executives include Michael Martin, Chief Operating Officer, and Joe Miller, Chief Financial Officer, who bring a wealth of expertise in operations, finance, and corporate strategy.

Core Business Segments

Aurinia Pharmaceuticals focuses on developing innovative therapies for autoimmune diseases, with a particular emphasis on lupus nephritis (LN), a severe kidney inflammation caused by systemic lupus erythematosus (SLE). The company’s core business segments include:

1. Autoimmune Disease Therapies

  • LUPKYNIS® (voclosporin): Aurinia’s flagship product, LUPKYNIS, is the first FDA-approved oral therapy for lupus nephritis. It is designed to improve kidney function and reduce the risk of kidney failure in patients with LN. LUPKYNIS represents a significant advancement in the treatment of this debilitating condition.

2. Research and Development (R&D)

  • Aurinia invests heavily in R&D to expand its pipeline of therapies for autoimmune diseases. The company is exploring additional indications for voclosporin and other potential treatments for rare autoimmune conditions.

3. Patient Support Services

  • Aurinia offers comprehensive patient support programs to ensure that individuals prescribed LUPKYNIS have access to the medication and the resources they need. These services include financial assistance, educational materials, and dedicated support teams.

Business Model

Aurinia’s business model is centered around the development, approval, and commercialization of innovative therapies for autoimmune diseases. The company generates revenue primarily through the sales of LUPKYNIS. By leveraging its expertise in clinical development and regulatory affairs, Aurinia has successfully brought LUPKYNIS to market and continues to expand its reach through strategic partnerships and collaborations.

The company also invests in ongoing clinical trials to explore new indications for its existing products and to develop novel therapies. This approach allows Aurinia to diversify its revenue streams and maintain a robust pipeline of potential treatments.

Strategic Direction

Aurinia Pharmaceuticals is committed to advancing the treatment of autoimmune diseases and improving patient outcomes. The company’s strategic priorities include:

  • Expanding the Indications for LUPKYNIS: Aurinia is conducting clinical trials to evaluate the efficacy of LUPKYNIS in other autoimmune conditions, such as focal segmental glomerulosclerosis (FSGS) and dry eye syndrome.
  • Geographic Expansion: The company aims to increase the global availability of LUPKYNIS by securing regulatory approvals in additional markets, including Europe and Asia.
  • Sustainability Goals: Aurinia is dedicated to minimizing its environmental impact and promoting sustainability across its operations. This includes reducing waste, optimizing energy use, and supporting community initiatives.
  • Pipeline Development: Aurinia continues to invest in R&D to identify and develop new therapies for autoimmune diseases, ensuring a steady flow of innovative treatments.

Competitive Landscape

Aurinia Pharmaceuticals operates in a highly competitive biopharmaceutical market. Key competitors include:

  • GlaxoSmithKline (GSK): GSK’s Benlysta is a leading treatment for systemic lupus erythematosus and lupus nephritis, posing direct competition to LUPKYNIS.
  • Roche: Roche develops therapies for autoimmune diseases, including Rituxan, which is used to treat certain forms of lupus.
  • Bristol-Myers Squibb (BMS): BMS offers Orencia, a treatment for autoimmune conditions such as rheumatoid arthritis, which competes in the broader autoimmune market.

Despite the competition, Aurinia differentiates itself through its focus on lupus nephritis and its innovative approach to treatment.

Risk Factors

Aurinia Pharmaceuticals faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company’s revenue is heavily reliant on the sales of LUPKYNIS. Any decline in demand or competition from alternative therapies could adversely affect its financial results.
  • Regulatory Challenges: The biopharmaceutical industry is subject to stringent regulatory requirements. Delays or failures in obtaining regulatory approvals for new products or indications could hinder Aurinia’s growth.
  • Supply Chain Disruptions: Disruptions in the supply chain, including shortages of raw materials or manufacturing issues, could impact the availability of LUPKYNIS.
  • Intellectual Property Risks: The expiration of patents or challenges to Aurinia’s intellectual property rights could expose the company to generic competition.

Recent Developments

Aurinia Pharmaceuticals has made significant strides in recent years:

  • FDA Approval of LUPKYNIS: The approval of LUPKYNIS marked a major milestone for Aurinia, establishing the company as a leader in the treatment of lupus nephritis.
  • Partnerships and Collaborations: Aurinia has entered into strategic partnerships with leading pharmaceutical companies to expand the reach of LUPKYNIS and accelerate the development of its pipeline.
  • Clinical Trials: The company is actively conducting clinical trials to evaluate new indications for LUPKYNIS and to develop additional therapies for autoimmune diseases.
  • Global Expansion: Aurinia is pursuing regulatory approvals in international markets to increase the availability of LUPKYNIS to patients worldwide.

Investment Considerations

Investors considering Aurinia Pharmaceuticals should weigh the following factors:

Strengths

  • Innovative Product Portfolio: LUPKYNIS is a groundbreaking therapy for lupus nephritis, addressing a significant unmet medical need.
  • Strong Leadership: Aurinia’s experienced management team has a proven track record of success in the biopharmaceutical industry.
  • Growth Potential: The company’s focus on expanding indications for LUPKYNIS and developing new therapies positions it for long-term growth.

Risks

  • Revenue Concentration: Aurinia’s reliance on LUPKYNIS as its primary revenue source poses a risk if demand declines or competition increases.
  • Regulatory and Clinical Risks: The success of Aurinia’s pipeline depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain.
  • Market Competition: The biopharmaceutical industry is highly competitive, with established players and new entrants vying for market share.

Conclusion

Aurinia Pharmaceuticals Inc. is a pioneering biopharmaceutical company focused on transforming the treatment of autoimmune diseases. With its innovative product portfolio, strong leadership, and commitment to R&D, Aurinia is well-positioned for future growth. While the company faces risks associated with market dependence and regulatory challenges, its strategic initiatives and focus on patient-centric solutions provide a solid foundation for long-term success. As Aurinia continues to expand its global footprint and develop new therapies, it remains a compelling investment opportunity in the biopharmaceutical sector.